Gayatri Bioorganics Limited (ISIN: INE052E01015) has announced a significant change in its key managerial personnel. The company's Board of Directors has approved the appointment of Ms. Huda Khan as the new Company Secretary and Compliance Officer, effective September 15, 2025.

Board Meeting Details

The decision was made during a board meeting held on September 15, 2025, at the company's registered office. The meeting commenced at 15:10 and concluded at 15:40, as per the official communication to the BSE Limited.

About Ms. Huda Khan

Ms. Khan brings a wealth of experience to her new role at Gayatri BioOrganics:

• Qualifications: She is a qualified Company Secretary.
• Experience: Ms. Khan has over 8 years of experience in secretarial work.
• Appointment Terms: Her appointment follows the existing norms for Key Managerial Personnel (KMPs) of the company.
• Shareholding: Ms. Khan does not hold any shares in the company.
• Relationships: She has no relationships with other directors of Gayatri BioOrganics Limited.

Regulatory Compliance

The appointment of Ms. Khan is in line with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has duly informed the BSE Limited about this appointment, adhering to the necessary disclosure requirements.

Company Leadership

The official communication to the BSE was signed by Mr. Sreedhara Reddy Kanaparthi, the Whole-time Director of Gayatri BioOrganics Limited, who holds the Director Identification Number (DIN) 09608890.

This appointment marks a new chapter for Gayatri BioOrganics as they strengthen their management team with experienced professionals. Ms. Khan's extensive background in secretarial work is expected to contribute significantly to the company's compliance and governance efforts.

Gayatri Bioorganics Limited (GBL) has announced its unaudited financial results for the first quarter of the fiscal year 2025-26, along with other significant corporate updates. The company's board of directors convened on July 29, 2025, to review and approve these developments.

Financial Results

The board approved the unaudited financial results for the quarter ended June 30, 2025, which were reviewed by the audit committee. While specific financial figures were not disclosed in the announcement, the company stated that the results were prepared in accordance with Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013.

Annual General Meeting

Gayatri Bioorganics has scheduled its 34th Annual General Meeting (AGM) for August 26, 2025. In line with ongoing digital trends, the AGM will be conducted via video conference or other audio-visual means (OAVM), allowing shareholders to participate remotely.

Directors' Report

The board also approved the 34th Directors' Report for the financial year 2024-25. This report, along with the notice for convening the 34th AGM, will provide shareholders with a comprehensive overview of the company's performance and future outlook.

Business Continuity

It's worth noting that the financial statements were prepared on a going concern basis. The company has received a comfort letter from its promoters, indicating their support for the continuation of business operations in the future. This assurance is crucial for stakeholders and reflects the promoters' confidence in the company's prospects.

Operational Focus

Gayatri Bioorganics Limited continues to operate as a single-segment business. The company has not disclosed any plans for diversification or expansion into new segments at this time.

Regulatory Compliance

The financial results and other corporate actions announced are in compliance with Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This adherence to regulatory standards underscores GBL's commitment to transparency and good corporate governance.

As Gayatri Bioorganics Limited moves forward, stakeholders will be keenly watching the upcoming AGM for more detailed insights into the company's performance and strategic direction for the remainder of the fiscal year 2025-26.